Skip to content
Disclosery

SR One Capital Management, LP

Follow

13F filer, CIK 1910264, Redwood City, CA

SR One Capital Management, LP reported $706,376,583 across 13 holdings for the quarter ended 2025-12-31, in a 13F-HR filed 2026-02-12. Its ten largest share positions make up 97.72% of the portfolio.

Filed (acceptance time not in the bulk data set), ingested 13F-HR 0001193125-26-048808

Period
2025-12-31
Reported value
$706M
Holdings
13
Top 10 weight
97.72%
New
1
Sold out
0

Largest buys vs the previous quarter

SecurityShares changeApprox. value
OCSadded+318,522$6.36M
ZBIOadded+126,315$4.59M
RAREnew+137,753$3.17M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
MLYSreduced-549,967-$20M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q4 2025

Share positions as resolved from 13F-HR 0001193125-26-048808, largest first. % of portfolio is the value over $706,376,583, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
ZBIOZENAS BIOPHARMA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 4,911,539 shares; 2024Q4: 4,911,539 shares; 2025Q1: 4,911,539 shares; 2025Q2: 4,911,539 shares; 2025Q3: 4,911,539 shares; 2025Q4: 5,037,854 shares 5,037,854$183M25.9%+126,315Timeline
ACLXARCELLX INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 2,346,630 shares; 2024Q4: 2,346,630 shares; 2025Q1: 2,346,630 shares; 2025Q2: 2,346,630 shares; 2025Q3: 2,346,630 shares; 2025Q4: 2,346,630 shares 2,346,630$153M21.66%0Timeline
CRSPCRISPR THERAPEUTICS AGQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 1,048,951 shares; 2024Q4: 1,048,951 shares; 2025Q1: 1,048,951 shares; 2025Q2: 1,048,951 shares; 2025Q3: 2,038,763 shares; 2025Q4: 2,038,763 shares 2,038,763$107M15.14%0Timeline
DSGNDESIGN THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 6,526,476 shares; 2024Q4: 6,526,476 shares; 2025Q1: 6,526,476 shares; 2025Q2: 6,526,476 shares; 2025Q3: 6,526,476 shares; 2025Q4: 6,526,476 shares 6,526,476$61.2M8.67%0Timeline
MLYSMINERALYS THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 2,016,822 shares; 2024Q4: 2,016,822 shares; 2025Q1: 3,127,933 shares; 2025Q2: 3,127,933 shares; 2025Q3: 2,113,933 shares; 2025Q4: 1,563,966 shares 1,563,966$56.8M8.03%-549,967Timeline
SPRYARS PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 4,012,903 shares; 2024Q4: 4,012,903 shares; 2025Q1: 4,012,903 shares; 2025Q2: 4,012,903 shares; 2025Q3: 4,012,903 shares; 2025Q4: 4,012,903 shares 4,012,903$46.8M6.62%0Timeline
ORICORIC PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 4,514,929 shares; 2025Q3: 4,514,929 shares; 2025Q4: 4,514,929 shares 4,514,929$37.8M5.34%0Timeline
ALMSALUMIS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 1,959,896 shares; 2024Q4: 1,959,896 shares; 2025Q1: 1,959,896 shares; 2025Q2: 1,959,896 shares; 2025Q3: 1,959,896 shares; 2025Q4: 1,959,896 shares 1,959,896$19.1M2.71%0Timeline
ORKAORUKA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 375,330 shares; 2024Q4: 430,330 shares; 2025Q1: 430,330 shares; 2025Q2: 430,330 shares; 2025Q3: 430,330 shares; 2025Q4: 430,330 shares 430,330$13M1.85%0Timeline
OCSOCULIS HOLDING AGQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: 322,500 shares; 2025Q2: 322,500 shares; 2025Q3: 322,500 shares; 2025Q4: 641,022 shares 641,022$12.8M1.81%+318,522Timeline
ENGNENGENE HOLDINGS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 747,750 shares; 2024Q4: 747,750 shares; 2025Q1: 747,750 shares; 2025Q2: 747,750 shares; 2025Q3: 747,750 shares; 2025Q4: 747,750 shares 747,750$6.75M0.96%0Timeline
NKTXNKARTA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 3,333,333 shares; 2024Q4: 3,333,333 shares; 2025Q1: 3,333,333 shares; 2025Q2: 3,333,333 shares; 2025Q3: 3,333,333 shares; 2025Q4: 3,333,333 shares 3,333,333$6.17M0.87%0Timeline
RAREULTRAGENYX PHARMACEUTICAL INQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 137,753 shares 137,753$3.17M0.45%newTimeline

How Q4 2025 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0001193125-26-048808 base2026-02-12acceptance time not in the bulk data set